Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852591 · ClinicalTrials.gov registry record · NA
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01852591 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 8 participants.
The verdict
NCT01852591, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune response.
Interventions
- BIOLOGICAL PCV 13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852591
The ClinicalTrials.gov registry entry for NCT01852591 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCV 13 is the first listed.
NCT01852591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852591 about?
NCT01852591 is a clinical study titled "Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant". There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune response.
What is the current status of trial NCT01852591?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2013-02. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01852591?
The interventions under investigation include: PCV 13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01852591?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.